Evidence map›Paper›PMID 41754439›Full record

ArticlePathogens (Basel, Switzerland)2026

Single Isothermal Assay for Multi-Site Mutation Detection of Rifampicin Resistance in

Nidhi Nandu, Michael Miller, Zhi-Xiang Lu

Abstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nidhi NanduRevvity, Inc., 77 4th Ave, Waltham, MA 02451, USA.ORCID 0000-0001-8138-4461
Michael MillerRevvity, Inc., 77 4th Ave, Waltham, MA 02451, USA.ORCID 0009-0006-3258-6132
Zhi-Xiang LuRevvity, Inc., 77 4th Ave, Waltham, MA 02451, USA.ORCID 0000-0001-9230-2169

Funding

Revvity (United States) N/A
6 · The paper itself

Abstract

Antimicrobial drug resistance is an escalating global health burden, often driven by multiple genetic changes within key resistance-associated genes. Achieving multiplex capability of mutation detection while maintaining simplicity and affordability is critical, particularly in point-of-care and resource-limited settings. Here, we introduce a strategy for multi-site mutation detection using single isothermal amplification of a nucleic acid fragment spanning multiple mutations in the rifampicin resistance-determining region (RRDR) of the

Indexed as

Antitubercular AgentsDrug Resistance, BacterialMolecular Diagnostic TechniquesMutationMycobacterium tuberculosisNucleic Acid Amplification TechniquesRifampinAntibiotics, AntitubercularBacterial ProteinsDNA, BacterialDNA-Directed RNA PolymerasesHumansMicrobial Sensitivity TestsRapid Diagnostic TestsSensitivity and SpecificityAntibiotics, AntitubercularAntitubercular AgentsBacterial ProteinsDNA, BacterialDNA-Directed RNA PolymerasesRifampinrpoB protein, Mycobacterium tuberculosisdrug resistanceLAMPMTBmulti-site mutationsMycobacterium tuberculosisrifampicin

Identifiers

PMID41754439
PMCPMC12943657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.